Table 2.
Selected Actively Recruiting CAR T Cell Clinical Studies for Solid Tumors and Brain Tumors
| Antigen | Diagnosis | Signaling Domain | Additional Engineering | Vector | T Cell Product | Other Therapy | NCT No.: ClinicalTrials.gov |
|---|---|---|---|---|---|---|---|
| Intravenous Administration, No Lymphodepleting Chemotherapy Listed onClinicalTrials.govSite | |||||||
| GPC3 | HCC | – | TGF-β-CAR, IL-7-CCL19 | – | ATCs | N | NCT03198546 |
| HCC | – | N | – | ATCs | N | NCT04121273 | |
| PSMA | solid tumors | – | N | – | ATCs | N | NCT04429451 |
| Intravenous Administration after Lymphodepleting Chemotherapy | |||||||
| B7-H3 | solid tumors | – | iC9 | LV | ATCs | N | NCT04432649 |
| CD171 | NB | 41BBζ or CD28.41BBζ | N | LV | ATCs | N | NCT02311621 |
| Claudin 18.2 | solid tumors | – | N | – | ATCs | N | NCT03874897 |
| EGFR806 | solid tumors | 41BBζ | CD19-CAR | LV | ATCs | N | NCT03618381 |
| IL-13Rα2 | Melanoma | 41BBζ | N | LV | ATCs | IL-2 | NCT04119024 |
| GD2 | NB | – | iC9, IL-15 | RV | ATCs | N | NCT03721068 |
| solid tumors | – | iC9 | – | ATCs | N | NCT03373097 | |
| solid tumors | – | C7R | RV | ATCs | N | NCT03635632 | |
| DIPG, HGG | – | C7R | RV | ATCs | N | NCT04099797 | |
| NB | – | IL-15 | RV | iNKT | N | NCT03294954 | |
| NB | – | N | – | ATCs | N | NCT02761915 | |
| DIPG | 41BBζ | iC9 | RV | ATCs | N | NCT04196413 | |
| GPC3 | solid tumors | 41BBζ | N | RV | ATCs | N | NCT02932956 |
| HCC | 41BBζ | N | RV | ATCs | N | NCT02905188 | |
| HCC | – | N | – | ATCs | N | NCT03884751 | |
| Mesothelin | solid tumors | – | PD-1 KO | – | ATCs | N | NCT03747965 |
| solid tumors | – | N | LV | ATCs | N | NCT03054298 | |
| MUC-1 | esophageal CA | – | PD-1 KO | – | ATCs | IL-2 | NCT03706326 |
| NSCLC | – | PD-1 KO | – | ATCs | IL-2 | NCT03525782 | |
| breast Cancer | 41BBζ | N | LV | ATCs | N | NCT04020575 | |
| PSCA | prostate CA | 41BBζ | N | LV | ATCs | N | NCT03873805 |
| solid tumors | ζ | iMC | RV | ATCs | N | NCT02744287 | |
| PSMA | solid tumors | – | iC9 | gene editing | ATCs | N | NCT04249947 |
| prostate CA | – | DNR TGFβ | LV | ATCs | N | NCT03089203 | |
| prostate CA | – | DNR TGF-β | LV | ATCs | N | NCT04227275 | |
| Intravenous and Locoregional Administration After Lymphodepleting Chemotherapy | |||||||
| MUC16ecto | solid tumors | 41BBζ | IL-12 | LV | ATCs | N | NCT02498912 |
| Locoregional Administration, No Lymphodepleting Chemotherapy | |||||||
| B7-H3 | CNS tumors | – | N | LV | ATCs | N | NCT04185038 |
| CNS tumors | – | N | RV | ATCs | TMZ | NCT04385173 | |
| CNS tumors | – | N | RV | ATCs | TMZ | NCT04077866 | |
| EGFR806 | CNS tumors | 41BBζ | N | LV | ATCs | N | NCT03618381 |
| EGFR family | SCCHN | CD28ζ | IL-4/IL-2 CCR | RV | ATCs | N | NCT01818323 |
| HER2 | CNS metastases | 41BBζ | N | LV | ATCs | N | NCT03696030 |
| CNS tumors | CD28ζ | N | RV | ATCs | N | NCT02442297 | |
| CNS tumors | 41BBζ | N | LV | ATCs | N | NCT03500991 | |
| IL-13Rα2 | HGG | 41BBζ | N | LV | ATCs | nivo/ipi | NCT04003649 |
| HGG | 41BBζ | N | LV | ATCs | N | NCT02208362 | |
| Locoregional Administration after Lymphodepleting Chemotherapy | |||||||
| FRα | OVCA | 41BBζ | N | LV | ATCs | N | NCT03585764 |
| Mesothelin | pleural disease | CD28ζ | iC9 | – | ATCs | Pembro | NCT02414269 |
ATC, activated T cell; CA, cancer; CCR, chimeric cytokine receptor; C7R, constitutive active IL-7 receptor α; DNR, dominant negative receptor; HCC, hepatocellular carcinoma; HGG, high-grade glioma; iC9, inducible caspase-9; iMC, inducible Myd88.CD40; ipi, ipilimumab; KO, knockout; LV, lentivirus; N, no; NB, neuroblastoma; nivo, nivolumab; OVCA, ovarian cancer; pembro, pembrolizumab; RV, retrovirus; SCCHN, squamous cell carcinoma of the head and neck; Y, yes.